Array Biopharma Inc (ARRY), InterMune Inc (ITMN): Three Humongous Health-Care Stocks This Week

Page 2 of 2

Esbriet was first launched in Germany in 2011. InterMune Inc (NASDAQ:ITMN) has rolled the drug out in 13 other European nations. However, the big U.S. market still remains to be tapped. The FDA rejected approval of Esbriet in 2010. InterMune Inc (NASDAQ:ITMN) has a late-stage test under way in the U.S. with results expected in the second quarter of 2014.

Best of the best
It’s a tough decision between this week’s humongous stocks as to which is the best pick. All three have had great years thus far and have potential to keep moving up.

All things considered, though, my hunch is to go with Array Biopharma Inc (NASDAQ:ARRY). It’s been a long time since a new allergic asthma drug has been introduced. Array Biopharma Inc (NASDAQ:ARRY) definitely needs a partner to tackle the huge asthma market. I think it will find one and do well in the years ahead.

The article 3 Humongous Health-Care Stocks This Week originally appeared on Fool.com is written by Keith Speights.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2